Thoughts
Omniome
Very low-cost genomic and proteomic sequencing in silicon
First Investment: 2014
EXIT - Acquisition (Pacific Biosciences: PACB)
Omniome developed a proprietary DNA sequencing platform that delivered more accurate short reads than competing systems. Pacific Biosciences acquired the company in 2021.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules